National Cancer Institute. Cancer Stat Facts: Myeloma. Accessed August 18, 2021. Available at: https://seer.cancer.gov/statfacts/html/mulmy.html

• PubMed
National Cancer Institute. Cancer Stat Facts: Myeloma. Accessed August 18, 2021. Available at: https://seer.cancer.gov/statfacts/html/mulmy.html)| false
• Search Google Scholar
• Export Citation

Kumar SK, Dispenzieri A, Lacy MQ, et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia 2014;28:1122–1128.

• PubMed
Kumar SK, Dispenzieri A, Lacy MQ, Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia 2014;28:1122–1128.)| false
• Search Google Scholar
• Export Citation

Pozzi S, Marcheselli L, Bari A, et al. Survival of multiple myeloma patients in the era of novel therapies confirms the improvement in patients younger than 75 years: a population-based analysis. Br J Haematol 2013;163:40–46.

• PubMed
Pozzi S, Marcheselli L, Bari A, Survival of multiple myeloma patients in the era of novel therapies confirms the improvement in patients younger than 75 years: a population-based analysis. Br J Haematol 2013;163:40–46.)| false
• Search Google Scholar
• Export Citation

Tuchman SA, Shapiro GR, Ershler WB, et al. Multiple myeloma in the very old: an IASIA conference report. J Natl Cancer Inst 2014;106:dju067.

• PubMed
Tuchman SA, Shapiro GR, Ershler WB, Multiple myeloma in the very old: an IASIA conference report. J Natl Cancer Inst 2014;106:dju067.)| false
• Search Google Scholar
• Export Citation

Costa LJ, Omel J, Brown EE. Recent trends in multiple myeloma incidence and survival by age, race and ethnicity in the US. Blood 2016;128:4774.

• PubMed
Costa LJ, Omel J, Brown EE. Recent trends in multiple myeloma incidence and survival by age, race and ethnicity in the US. Blood 2016;128:4774.)| false
• Search Google Scholar
• Export Citation

Kint N, Delforge M. Concise review ‐ treatment of multiple myeloma in the very elderly: how do novel agents fit in? J Geriatr Oncol 2016;7:383–389.

• PubMed
Kint N, Delforge M. Concise review ‐ treatment of multiple myeloma in the very elderly: how do novel agents fit in? J Geriatr Oncol 2016;7:383–389.)| false
• Search Google Scholar
• Export Citation

Pawlyn C, Cairns D, Kaiser M, et al. The relative importance of factors predicting outcome for myeloma patients at different ages: results from 3894 patients in the Myeloma XI trial. Leukemia 2020;34:604–612.

• PubMed
Pawlyn C, Cairns D, Kaiser M, The relative importance of factors predicting outcome for myeloma patients at different ages: results from 3894 patients in the Myeloma XI trial. Leukemia 2020;34:604–612.)| false
• Search Google Scholar
• Export Citation

Gavriatopoulou M, Fotiou D, Koloventzou U, et al. Vulnerability variables among octogenarian myeloma patients: a single-center analysis of 110 patients. Leuk Lymphoma 2019;60:619–628.

• PubMed
Gavriatopoulou M, Fotiou D, Koloventzou U, Vulnerability variables among octogenarian myeloma patients: a single-center analysis of 110 patients. Leuk Lymphoma 2019;60:619–628.)| false
• Search Google Scholar
• Export Citation

Smith BD, Smith GL, Hurria A, et al. Future of cancer incidence in the United States: burdens upon an aging, changing nation. J Clin Oncol 2009;27:2758–2765.

• PubMed
Smith BD, Smith GL, Hurria A, Future of cancer incidence in the United States: burdens upon an aging, changing nation. J Clin Oncol 2009;27:2758–2765.)| false
• Search Google Scholar
• Export Citation

Palumbo A, Bringhen S, Mateos MV, et al. Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. Blood 2015;125:2068–2074.

• PubMed
Palumbo A, Bringhen S, Mateos MV, Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. Blood 2015;125:2068–2074.)| false
• Search Google Scholar
• Export Citation

Fried LP, Ferrucci L, Darer J, et al. Untangling the concepts of disability, frailty, and comorbidity: implications for improved targeting and care. J Gerontol A Biol Sci Med Sci 2004;59:255–263.

• PubMed
Fried LP, Ferrucci L, Darer J, Untangling the concepts of disability, frailty, and comorbidity: implications for improved targeting and care. J Gerontol A Biol Sci Med Sci 2004;59:255–263.)| false
• Search Google Scholar
• Export Citation

Engelhardt M, Domm AS, Dold SM, et al. A concise revised Myeloma Comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients. Haematologica 2017;102:910–921.

• PubMed
Engelhardt M, Domm AS, Dold SM, A concise revised Myeloma Comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients. Haematologica 2017;102:910–921.)| false
• Search Google Scholar
• Export Citation

Sandra Maria D, Mandy-Deborah M, Gabriele I, et al. Validation of the revised myeloma comorbidity index and other comorbidity scores in a multicenter German study group multiple myeloma trial. Haematologica 2020;106:875–880.

• PubMed
Sandra Maria D, Mandy-Deborah M, Gabriele I, Validation of the revised myeloma comorbidity index and other comorbidity scores in a multicenter German study group multiple myeloma trial. Haematologica 2020;106:875–880.)| false
• Search Google Scholar
• Export Citation

Cook G, Royle KL, Pawlyn C, et al. A clinical prediction model for outcome and therapy delivery in transplant-ineligible patients with myeloma (UK Myeloma Research Alliance Risk Profile): a development and validation study. Lancet Haematol 2019;6:e154–166.

• PubMed
Cook G, Royle KL, Pawlyn C, A clinical prediction model for outcome and therapy delivery in transplant-ineligible patients with myeloma (UK Myeloma Research Alliance Risk Profile): a development and validation study. Lancet Haematol 2019;6:e154–166.)| false
• Search Google Scholar
• Export Citation

Milani P, Vincent Rajkumar S, Merlini G, et al. N-terminal fragment of the type-B natriuretic peptide (NT-proBNP) contributes to a simple new frailty score in patients with newly diagnosed multiple myeloma. Am J Hematol 2016;91:1129–1134.

• PubMed
Milani P, Vincent Rajkumar S, Merlini G, N-terminal fragment of the type-B natriuretic peptide (NT-proBNP) contributes to a simple new frailty score in patients with newly diagnosed multiple myeloma. Am J Hematol 2016;91:1129–1134.)| false
• Search Google Scholar
• Export Citation

Facon T, Dimopoulos MA, Meuleman N, et al. A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial. Leukemia 2020;34:224–233.

• PubMed
Facon T, Dimopoulos MA, Meuleman N, A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial. Leukemia 2020;34:224–233.)| false
• Search Google Scholar
• Export Citation

Stege CAM, van der Holt B, Dinmohamed AG, et al. Validation of the FIRST simplified frailty scale using the ECOG performance status instead of patient-reported activities. Leukemia 2020;34:1964–1966.

• PubMed
Stege CAM, van der Holt B, Dinmohamed AG, Validation of the FIRST simplified frailty scale using the ECOG performance status instead of patient-reported activities. Leukemia 2020;34:1964–1966.)| false
• Search Google Scholar
• Export Citation

Palumbo A, Bringhen S, Caravita T, et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 2006;367:825–831.

• PubMed
Palumbo A, Bringhen S, Caravita T, Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 2006;367:825–831.)| false
• Search Google Scholar
• Export Citation

Palumbo A, Bringhen S, Liberati AM, et al. Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial. Blood 2008;112:3107–3114.

• PubMed
Palumbo A, Bringhen S, Liberati AM, Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial. Blood 2008;112:3107–3114.)| false
• Search Google Scholar
• Export Citation

Hulin C, Facon T, Rodon P, et al. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial. J Clin Oncol 2009;27:3664–3670.

• PubMed
Hulin C, Facon T, Rodon P, Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial. J Clin Oncol 2009;27:3664–3670.)| false
• Search Google Scholar
• Export Citation

Palumbo A, Hajek R, Delforge M, et al. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med 2012;366:1759–1769.

• PubMed
Palumbo A, Hajek R, Delforge M, Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med 2012;366:1759–1769.)| false
• Search Google Scholar
• Export Citation

Zweegman S, van der Holt B, Mellqvist UH, et al. Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma. Blood 2016;127:1109–1116.

• PubMed
Zweegman S, van der Holt B, Mellqvist UH, Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma. Blood 2016;127:1109–1116.)| false
• Search Google Scholar
• Export Citation

Facon T, Lee JH, Moreau P, et al. Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma. Blood 2019;133:1953–1963.

• PubMed
Facon T, Lee JH, Moreau P, Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma. Blood 2019;133:1953–1963.)| false
• Search Google Scholar
• Export Citation

Morgan GJ, Davies FE, Gregory WM, et al. Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation. Blood 2011;118:1231–1238.

• PubMed
Morgan GJ, Davies FE, Gregory WM, Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation. Blood 2011;118:1231–1238.)| false
• Search Google Scholar
• Export Citation

Bringhen S, Petrucci MT, Larocca A, et al. Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study. Blood 2014;124:63–69.

• PubMed
Bringhen S, Petrucci MT, Larocca A, Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study. Blood 2014;124:63–69.)| false
• Search Google Scholar
• Export Citation

Dimopoulos MA, Grosicki S, Jędrzejczak WW, et al. All-oral ixazomib, cyclophosphamide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma. Eur J Cancer 2019;106:89–98.

• PubMed
Dimopoulos MA, Grosicki S, Jędrzejczak WW, All-oral ixazomib, cyclophosphamide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma. Eur J Cancer 2019;106:89–98.)| false
• Search Google Scholar
• Export Citation

Benboubker L, Dimopoulos MA, Dispenzieri A, et al. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med 2014;371:906–917.

• PubMed
Benboubker L, Dimopoulos MA, Dispenzieri A, Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med 2014;371:906–917.)| false
• Search Google Scholar
• Export Citation

Facon T, Dimopoulos MA, Dispenzieri A, et al. Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma. Blood 2018;131:301–310.

• PubMed
Facon T, Dimopoulos MA, Dispenzieri A, Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma. Blood 2018;131:301–310.)| false
• Search Google Scholar
• Export Citation

Magarotto V, Bringhen S, Offidani M, et al. Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma. Blood 2016;127:1102–1108.

• PubMed
Magarotto V, Bringhen S, Offidani M, Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma. Blood 2016;127:1102–1108.)| false
• Search Google Scholar
• Export Citation

Bringhen S, D’Agostino M, Paris L, et al. Lenalidomide-based induction and maintenance in elderly newly diagnosed multiple myeloma patients: updated results of the EMN01 randomized trial. Haematologica 2020;105:1937–1947.

• PubMed
Bringhen S, D’Agostino M, Paris L, Lenalidomide-based induction and maintenance in elderly newly diagnosed multiple myeloma patients: updated results of the EMN01 randomized trial. Haematologica 2020;105:1937–1947.)| false
• Search Google Scholar
• Export Citation

Durie BGM, Hoering A, Abidi MH, et al. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet 2017;389:519–527.

• PubMed
Durie BGM, Hoering A, Abidi MH, Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet 2017;389:519–527.)| false
• Search Google Scholar
• Export Citation

Durie BGM, Hoering A, Sexton R, et al. Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT). Blood Cancer J 2020;10:53.

• PubMed
Durie BGM, Hoering A, Sexton R, Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT). Blood Cancer J 2020;10:53.)| false
• Search Google Scholar
• Export Citation

Kumar SK, Jacobus SJ, Cohen AD, et al. Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol 2020;21:1317–1330.

• PubMed
Kumar SK, Jacobus SJ, Cohen AD, Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol 2020;21:1317–1330.)| false
• Search Google Scholar
• Export Citation

Facon T, Venner CP, Bahlis NJ, et al. Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma. Blood 2021;137:3616–3628.

• PubMed
Facon T, Venner CP, Bahlis NJ, Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma. Blood 2021;137:3616–3628.)| false
• Search Google Scholar
• Export Citation

Mateos MV, Cavo M, Blade J, et al. Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial. Lancet 2020;395:132–141.

• PubMed
Mateos MV, Cavo M, Blade J, Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial. Lancet 2020;395:132–141.)| false
• Search Google Scholar
• Export Citation

Mateos MV, Dimopoulos MA, Cavo M, et al. Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma. N Engl J Med 2018;378:518–528.

• PubMed
Mateos MV, Dimopoulos MA, Cavo M, Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma. N Engl J Med 2018;378:518–528.)| false
• Search Google Scholar
• Export Citation

Facon T, Kumar SK, Plesner T, et al. Overall survival results with daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: phase 3 MAIA study. Presented at the EHA2021 Virtual Congress; June 9–17, 2021. Abstract LB1901.

• PubMed
Facon T, Kumar SK, Plesner T, Overall survival results with daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: phase 3 MAIA study. Presented at the EHA2021 Virtual Congress; June 9–17, 2021. Abstract LB1901.)| false
• Search Google Scholar
• Export Citation

Facon T, Kumar S, Plesner T, et al. Daratumumab plus lenalidomide and dexamethasone for untreated myeloma. N Engl J Med 2019;380:2104–2115.

• PubMed
Facon T, Kumar S, Plesner T, Daratumumab plus lenalidomide and dexamethasone for untreated myeloma. N Engl J Med 2019;380:2104–2115.)| false
• Search Google Scholar
• Export Citation

San-Miguel J, Avet-Loiseau H, Paiva B, et al. Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE. Blood 2022;139:492–501.

• PubMed
San-Miguel J, Avet-Loiseau H, Paiva B, Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE. Blood 2022;139:492–501.)| false
• Search Google Scholar
• Export Citation

Moreau P, Sonneveld P. Daratumumab (DARA) maintenance or observation (OBS) after treatment with bortezomib, thalidomide and dexamethasone (VTd) with or without DARA and autologous stem cell transplant (ASCT) in patients (pts) with newly diagnosed multiple myeloma (NDMM): CASSIOPEIA Part 2. J Clin Oncol 2021;39(Suppl):Abstract 8004.

• PubMed
Moreau P, Sonneveld P. Daratumumab (DARA) maintenance or observation (OBS) after treatment with bortezomib, thalidomide and dexamethasone (VTd) with or without DARA and autologous stem cell transplant (ASCT) in patients (pts) with newly diagnosed multiple myeloma (NDMM): CASSIOPEIA Part 2. J Clin Oncol 2021;39(Suppl):Abstract 8004.)| false
• Search Google Scholar
• Export Citation

Fonseca R, Usmani SZ, Mehra M, et al. Frontline treatment patterns and attrition rates by subsequent lines of therapy in patients with newly diagnosed multiple myeloma. BMC Cancer 2020;20:1087.

• PubMed
Fonseca R, Usmani SZ, Mehra M, Frontline treatment patterns and attrition rates by subsequent lines of therapy in patients with newly diagnosed multiple myeloma. BMC Cancer 2020;20:1087.)| false
• Search Google Scholar
• Export Citation

Zweegman S, Usmani SZ, Chastain K, et al. Bortezomib, lenalidomide, and dexamethasone (VRd) ± daratumumab (DARA) in patients (pts) with newly diagnosed multiple myeloma (NDMM) for whom transplant is not planned as initial therapy: a multicenter, randomized, phase III study (CEPHEUS). J Clin Oncol 2019;37(Suppl):Abstract TPS8056.

• PubMed
Zweegman S, Usmani SZ, Chastain K, Bortezomib, lenalidomide, and dexamethasone (VRd) ± daratumumab (DARA) in patients (pts) with newly diagnosed multiple myeloma (NDMM) for whom transplant is not planned as initial therapy: a multicenter, randomized, phase III study (CEPHEUS). J Clin Oncol 2019;37(Suppl):Abstract TPS8056.)| false
• Search Google Scholar
• Export Citation

O’Donnell EK, Laubach JP, Yee AJ, et al. A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma. Br J Haematol 2018;182:222–230.

• PubMed
O’Donnell EK, Laubach JP, Yee AJ, A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma. Br J Haematol 2018;182:222–230.)| false
• Search Google Scholar
• Export Citation

O’Donnell EK, Laubach JP, Yee AJ, et al. Updated results of a phase 2 study of modified lenalidomide, bortezomib, and dexamethasone (RVd-lite) in transplant-ineligible multiple myeloma. Blood 2019;134(Suppl 1):3178.

• PubMed
O’Donnell EK, Laubach JP, Yee AJ, Updated results of a phase 2 study of modified lenalidomide, bortezomib, and dexamethasone (RVd-lite) in transplant-ineligible multiple myeloma. Blood 2019;134(Suppl 1):3178.)| false
• Search Google Scholar
• Export Citation

Larocca A, Salvini M, De Paoli L, et al. Efficacy and feasibility of dose/schedule-adjusted Rd-R Vs. continuous Rd in elderly and intermediate-fit newly diagnosed multiple myeloma (NDMM) patients: RV-MM-PI-0752 phase III randomized study. Blood 2018;132(Suppl 1):305.

• PubMed
Larocca A, Salvini M, De Paoli L, Efficacy and feasibility of dose/schedule-adjusted Rd-R Vs. continuous Rd in elderly and intermediate-fit newly diagnosed multiple myeloma (NDMM) patients: RV-MM-PI-0752 phase III randomized study. Blood 2018;132(Suppl 1):305.)| false
• Search Google Scholar
• Export Citation

Larocca A, Bonello F, Gaidano G, et al. Dose/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma. Blood 2021;137:3027–3036.

• PubMed
Larocca A, Bonello F, Gaidano G, Dose/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma. Blood 2021;137:3027–3036.)| false
• Search Google Scholar
• Export Citation

Askeland FB, Haukås E, Slørdahl TS, et al. Replacing steroids in transplant-ineligible multiple myeloma: the phase 2 isatuximab-bortezomib-lenalidomide-dexamethasone rest study. Blood 2023;142(Suppl 1):3381.

• PubMed
Askeland FB, Haukås E, Slørdahl TS, Replacing steroids in transplant-ineligible multiple myeloma: the phase 2 isatuximab-bortezomib-lenalidomide-dexamethasone rest study. Blood 2023;142(Suppl 1):3381.)| false
• Search Google Scholar
• Export Citation

Manier S, Corre J, Hulin C, et al. A dexamethasone sparing-regimen with daratumumab and lenalidomide in frail patients with newly-diagnosed multiple myeloma: efficacy and safety analysis of the phase 3 IFM2017-03 trial. Blood 2022;140(Suppl 1):1369–1370.

• PubMed
Manier S, Corre J, Hulin C, A dexamethasone sparing-regimen with daratumumab and lenalidomide in frail patients with newly-diagnosed multiple myeloma: efficacy and safety analysis of the phase 3 IFM2017-03 trial. Blood 2022;140(Suppl 1):1369–1370.)| false
• Search Google Scholar
• Export Citation

Stege CAM, Nasserinejad K, van der Spek E, et al. Ixazomib, daratumumab, and low-dose dexamethasone in frail patients with newly diagnosed multiple myeloma: the Hovon 143 study. J Clin Oncol 2021;39:2758–2767.

• PubMed
Stege CAM, Nasserinejad K, van der Spek E, Ixazomib, daratumumab, and low-dose dexamethasone in frail patients with newly diagnosed multiple myeloma: the Hovon 143 study. J Clin Oncol 2021;39:2758–2767.)| false
• Search Google Scholar
• Export Citation

Facon T, Hulin C, Dimopoulos MA, et al. A frailty scale predicts outcomes of patients with newly diagnosed multiple myeloma who are ineligible for transplant treated with continuous lenalidomide plus low-dose dexamethasone on the first trial. Blood 2015;126(Suppl 1):4239.

• PubMed
Facon T, Hulin C, Dimopoulos MA, A frailty scale predicts outcomes of patients with newly diagnosed multiple myeloma who are ineligible for transplant treated with continuous lenalidomide plus low-dose dexamethasone on the first trial. Blood 2015;126(Suppl 1):4239.)| false
• Search Google Scholar
• Export Citation

Mateos MV, Dimopoulos MA, Cavo M, et al. Daratumumab plus bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of ALCYONE. Clin Lymphoma Myeloma Leuk 2021;21:785–798.

• PubMed
Mateos MV, Dimopoulos MA, Cavo M, Daratumumab plus bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of ALCYONE. Clin Lymphoma Myeloma Leuk 2021;21:785–798.)| false
• Search Google Scholar
• Export Citation

Facon T, Cook G, Usmani SZ, et al. Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA. Leukemia 2022;36:1066–1077.

• PubMed
Facon T, Cook G, Usmani SZ, Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA. Leukemia 2022;36:1066–1077.)| false
• Search Google Scholar
• Export Citation

Bringhen S, Antonioli E, Gamberi B, et al. Carfilzomib-lenalidomide- dexamethasone (KRd) vs. lenalidomide-dexamethasone (Rd) in newly diagnosed fit or intermediate-fit multiple myeloma patients not eligible for autologous stem-cell transplantation (phase III EMN20 trial): analysis of sustained undetectable minimal residual disease (MRD). Blood 2023;142(Suppl 1):205.

• PubMed
Bringhen S, Antonioli E, Gamberi B, Carfilzomib-lenalidomide- dexamethasone (KRd) vs. lenalidomide-dexamethasone (Rd) in newly diagnosed fit or intermediate-fit multiple myeloma patients not eligible for autologous stem-cell transplantation (phase III EMN20 trial): analysis of sustained undetectable minimal residual disease (MRD). Blood 2023;142(Suppl 1):205.)| false
• Search Google Scholar
• Export Citation

Compare lenalidomide and subcutaneous daratumumab vs lenalidomide and dexamethasone in frail subjects with previously untreated multiple myeloma who are ineligible for high dose therapy (IFM2017_03). Accessed July 27, 2023. Available at: https://clinicaltrials.gov/ct2/show/NCT03993912

• PubMed
Compare lenalidomide and subcutaneous daratumumab vs lenalidomide and dexamethasone in frail subjects with previously untreated multiple myeloma who are ineligible for high dose therapy (IFM2017_03). Accessed July 27, 2023. Available at: https://clinicaltrials.gov/ct2/show/NCT03993912)| false
• Export Citation

Mateos MV, Paiva B, Cedena Romero MT, et al. GEM2017FIT trial: induction therapy with bortezomib-melphalan and prednisone (VMP) followed by lenalidomide and dexamethasone (Rd) versus carfilzomib, lenalidomide and dexamethasone (KRd) plus/minus daratumumab (D), 18 cycles, followed by consolidation and maintenance therapy with lenalidomide and daratumumab: phase III, multicenter, randomized trial for elderly fit newly diagnosed multiple myeloma (NDMM) patients aged between 65 and 80 years. Blood 2023;142(Suppl 1):209.

• PubMed
Mateos MV, Paiva B, Cedena Romero MT, GEM2017FIT trial: induction therapy with bortezomib-melphalan and prednisone (VMP) followed by lenalidomide and dexamethasone (Rd) versus carfilzomib, lenalidomide and dexamethasone (KRd) plus/minus daratumumab (D), 18 cycles, followed by consolidation and maintenance therapy with lenalidomide and daratumumab: phase III, multicenter, randomized trial for elderly fit newly diagnosed multiple myeloma (NDMM) patients aged between 65 and 80 years. Blood 2023;142(Suppl 1):209.)| false
• Search Google Scholar
• Export Citation

Cairns D, Pawlyn C, Royle KL, et al. Frailty-adjusted therapy in transplant non-eligible patients with newly diagnosed multiple myeloma (FiTNEss): a UK Myeloma Research Alliance Study, Myeloma XIV. Blood 2019;134(Suppl 1):3153.

• PubMed
Cairns D, Pawlyn C, Royle KL, Frailty-adjusted therapy in transplant non-eligible patients with newly diagnosed multiple myeloma (FiTNEss): a UK Myeloma Research Alliance Study, Myeloma XIV. Blood 2019;134(Suppl 1):3153.)| false
• Search Google Scholar
• Export Citation

Akhtar OS, Sheeba BA, Azad F, et al. Safety and efficacy of anti-BCMA CAR-T cell therapy in older adults with multiple myeloma: a systematic review and meta-analysis. J Geriatr Oncol 2024;15:101628.

• PubMed
Akhtar OS, Sheeba BA, Azad F, Safety and efficacy of anti-BCMA CAR-T cell therapy in older adults with multiple myeloma: a systematic review and meta-analysis. J Geriatr Oncol 2024;15:101628.)| false
• Search Google Scholar
• Export Citation

Moreau P, Garfall AL, van de Donk NWCJ, et al. Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med 2022;387:495–505.

• PubMed
Moreau P, Garfall AL, van de Donk NWCJ, Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med 2022;387:495–505.)| false
• Search Google Scholar
• Export Citation

Grosicki S, Yeh SP, Huang JSY, et al. MagnetisMM-6: an open-label, multicenter, randomized phase 3 study of elranatamab + daratumumab + lenalidomide (EDR) versus daratumumab + lenalidomide + dexamethasone (DRd) in transplant ineligible (TI) patients with newly diagnosed multiple myeloma (NDMM). J Clin Oncol 2023;41(Suppl): Abstract TPS8065.

• PubMed
Grosicki S, Yeh SP, Huang JSY, MagnetisMM-6: an open-label, multicenter, randomized phase 3 study of elranatamab + daratumumab + lenalidomide (EDR) versus daratumumab + lenalidomide + dexamethasone (DRd) in transplant ineligible (TI) patients with newly diagnosed multiple myeloma (NDMM). J Clin Oncol 2023;41(Suppl): Abstract TPS8065.)| false
• Search Google Scholar
• Export Citation

Krishnan AY, Manier S, Terpos E, et al. MajesTEC-7: a phase 3, randomized study of teclistamab + daratumumab + lenalidomide (Tec-DR) versus daratumumab + lenalidomide + dexamethasone (DRd) in patients with newly diagnosed multiple myeloma who are either ineligible or not intended for autologous stem cell transplant. Blood 2022;140(Suppl 1):10148–10149.

• PubMed
Krishnan AY, Manier S, Terpos E, MajesTEC-7: a phase 3, randomized study of teclistamab + daratumumab + lenalidomide (Tec-DR) versus daratumumab + lenalidomide + dexamethasone (DRd) in patients with newly diagnosed multiple myeloma who are either ineligible or not intended for autologous stem cell transplant. Blood 2022;140(Suppl 1):10148–10149.)| false
• Search Google Scholar
• Export Citation

Dytfeld D, Dhakal B, Agha M, et al. Bortezomib, lenalidomide and dexamethasone (VRd) followed by ciltacabtagene autoleucel versus Vrd followed by lenalidomide and dexamethasone (Rd) maintenance in patients with newly diagnosed multiple myeloma not intended for transplant: a randomized, phase 3 study (CARTITUDE-5). Blood 2021;138(Suppl 1):1835.

• PubMed
Dytfeld D, Dhakal B, Agha M, Bortezomib, lenalidomide and dexamethasone (VRd) followed by ciltacabtagene autoleucel versus Vrd followed by lenalidomide and dexamethasone (Rd) maintenance in patients with newly diagnosed multiple myeloma not intended for transplant: a randomized, phase 3 study (CARTITUDE-5). Blood 2021;138(Suppl 1):1835.)| false
• Search Google Scholar
• Export Citation

Orlowski RZ, Goldschmidt H, Cavo M, et al. Phase III (IMROZ) study design: isatuximab plus bortezomib (V), lenalidomide (R), and dexamethasone (d) vs VRd in transplant-ineligible patients (pts) with newly diagnosed multiple myeloma (NDMM). J Clin Oncol 2018;36(Suppl): Abstract TPS8055.

• PubMed
Orlowski RZ, Goldschmidt H, Cavo M, Phase III (IMROZ) study design: isatuximab plus bortezomib (V), lenalidomide (R), and dexamethasone (d) vs VRd in transplant-ineligible patients (pts) with newly diagnosed multiple myeloma (NDMM). J Clin Oncol 2018;36(Suppl): Abstract TPS8055.)| false
• Search Google Scholar
• Export Citation

Dimopoulos MA, Richardson PG, Bahlis NJ, et al. Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open- label, multicentre, randomised, phase 3 trial. Lancet Haematol 2022;9:e403–414.

• PubMed
Dimopoulos MA, Richardson PG, Bahlis NJ, Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open- label, multicentre, randomised, phase 3 trial. Lancet Haematol 2022;9:e403–414.)| false
• Search Google Scholar
• Export Citation

Askeland FB, Haukås E, Slørdahl TS, et al. Replacing steroids in transplant-ineligible multiple myeloma: the phase 2 isatuximab-bortezomib-lenalidomide-dexamethasone rest study. Blood 2023;142:381.

• PubMed
Askeland FB, Haukås E, Slørdahl TS, Replacing steroids in transplant-ineligible multiple myeloma: the phase 2 isatuximab-bortezomib-lenalidomide-dexamethasone rest study. Blood 2023;142:381.)| false
• Search Google Scholar
• Export Citation

Munshi PN, Vesole D, Jurczyszyn A, et al. Age no bar: a CIBMTR analysis of elderly patients undergoing autologous hematopoietic cell transplantation for multiple myeloma. Cancer 2020;126:5077–5087.

• PubMed
Munshi PN, Vesole D, Jurczyszyn A, Age no bar: a CIBMTR analysis of elderly patients undergoing autologous hematopoietic cell transplantation for multiple myeloma. Cancer 2020;126:5077–5087.)| false
• Search Google Scholar
• Export Citation

Munshi NC, Anderson LD Jr, Shah N, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med 2021;384:705–716.

• PubMed
Munshi NC, Anderson LD Jr, Shah N, Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med 2021;384:705–716.)| false
• Search Google Scholar
• Export Citation

Bobin A, Lambert J, Perrot A, et al. Multicenter open label phase 3 study of isatuximab plus lenalidomide and dexamethasone with/without bortezomib in the treatment of newly diagnosed non-frail transplant ineligible multiple myeloma elderly patients (≥ 65; < 80 years). IFM2020-05/Benefit. Blood 2022;140(Suppl 1):4423–4425.

• PubMed
Bobin A, Lambert J, Perrot A, Multicenter open label phase 3 study of isatuximab plus lenalidomide and dexamethasone with/without bortezomib in the treatment of newly diagnosed non-frail transplant ineligible multiple myeloma elderly patients (≥ 65; < 80 years). IFM2020-05/Benefit. Blood 2022;140(Suppl 1):4423–4425.)| false
• Search Google Scholar
• Export Citation

Palumbo A, Bringhen S, Mateos MV, et al. Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. Blood 2015;125:2068–2074.

• PubMed
Palumbo A, Bringhen S, Mateos MV, Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. Blood 2015;125:2068–2074.)| false
• Search Google Scholar
• Export Citation

Facon T, Dimopoulos MA, Meuleman N, et al. A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial. Leukemia 2020;34:224–233.

• PubMed
Facon T, Dimopoulos MA, Meuleman N, A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial. Leukemia 2020;34:224–233.)| false
• Search Google Scholar
• Export Citation

Kleber M, Ihorst G, Terhorst M, et al. Comorbidity as a prognostic variable in multiple myeloma: comparative evaluation of common comorbidity scores and use of a novel MM-comorbidity score. Blood Cancer J 2011;1:e35.

• PubMed
Kleber M, Ihorst G, Terhorst M, Comorbidity as a prognostic variable in multiple myeloma: comparative evaluation of common comorbidity scores and use of a novel MM-comorbidity score. Blood Cancer J 2011;1:e35.)| false
• Search Google Scholar
• Export Citation

Bonanad S, De la Rubia J, Gironella M, et al. Development and psychometric validation of a brief comprehensive health status assessment scale in older patients with hematological malignancies: the GAH Scale. J Geriatr Oncol 2015;6:353–361.

• PubMed
Bonanad S, De la Rubia J, Gironella M, Development and psychometric validation of a brief comprehensive health status assessment scale in older patients with hematological malignancies: the GAH Scale. J Geriatr Oncol 2015;6:353–361.)| false
• Search Google Scholar
• Export Citation

Larocca A, Bonello F, Gaidano G, et al. Dose/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma. Blood 2021;137:3027–3036.

• PubMed
Larocca A, Bonello F, Gaidano G, Dose/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma. Blood 2021;137:3027–3036.)| false
• Search Google Scholar
• Export Citation

Dimopoulos MA, Grosicki S, Jędrzejczak WW, et al. All-oral ixazomib, cyclophosphamide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma. Eur J Cancer 2019;106:89–98.

• PubMed
Dimopoulos MA, Grosicki S, Jędrzejczak WW, All-oral ixazomib, cyclophosphamide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma. Eur J Cancer 2019;106:89–98.)| false
• Search Google Scholar
• Export Citation

Zweegman S, Schjesvold FH, van der Holt B, et al. Ixazomib-thalidomide-low dose dexamethasone (ITd) induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-126/NMSG 21#13 trial. Blood 2018;132:800.

• PubMed
Zweegman S, Schjesvold FH, van der Holt B, Ixazomib-thalidomide-low dose dexamethasone (ITd) induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-126/NMSG 21#13 trial. Blood 2018;132:800.)| false
• Search Google Scholar
• Export Citation

Zweegman S, Levin MD, Klein SK, et al. Feasibility and efficacy of dose adjusted melphalan - prednisone - bortezomib (MPV) in elderly patients ≥ 75 years of age with newly diagnosed multiple myeloma; the non-randomised phase II HOVON 123 study. Blood 2016;128:3305.

• PubMed
Zweegman S, Levin MD, Klein SK, Feasibility and efficacy of dose adjusted melphalan - prednisone - bortezomib (MPV) in elderly patients ≥ 75 years of age with newly diagnosed multiple myeloma; the non-randomised phase II HOVON 123 study. Blood 2016;128:3305.)| false
• Search Google Scholar
• Export Citation

Stege CAM, Nasserinejad K, Levin MD, et al. Geriatric impairments and low muscle mass are associated with treatment discontinuation and overall survival in newly diagnosed non-transplant eligible multiple myeloma patients (nte-NDMM) treated with dose-adjusted melphalan-prednisone-bortezomib (MPV)—results of the Dutch HOVON 123 study. Blood 2018;132:1889.

• PubMed
Stege CAM, Nasserinejad K, Levin MD, Geriatric impairments and low muscle mass are associated with treatment discontinuation and overall survival in newly diagnosed non-transplant eligible multiple myeloma patients (nte-NDMM) treated with dose-adjusted melphalan-prednisone-bortezomib (MPV)—results of the Dutch HOVON 123 study. Blood 2018;132:1889.)| false
• Search Google Scholar
• Export Citation

Larocca A, Bringhen S, Petrucci MT, et al. A phase 2 study of three low-dose intensity subcutaneous bortezomib regimens in elderly frail patients with untreated multiple myeloma. Leukemia 2016;30:1320–1326.

• PubMed
Larocca A, Bringhen S, Petrucci MT, A phase 2 study of three low-dose intensity subcutaneous bortezomib regimens in elderly frail patients with untreated multiple myeloma. Leukemia 2016;30:1320–1326.)| false
• Search Google Scholar
• Export Citation

Sara B, Mattia DA, Laura P, et al. Lenalidomide-based induction and maintenance in elderly newly diagnosed multiple myeloma patients: updated results of the EMN01 randomized trial. Haematologica 2020;105:1937–1947.

• PubMed
Sara B, Mattia DA, Laura P, Lenalidomide-based induction and maintenance in elderly newly diagnosed multiple myeloma patients: updated results of the EMN01 randomized trial. Haematologica 2020;105:1937–1947.)| false
• Search Google Scholar
• Export Citation